

From the Editorial Board

A Note From the Editor in Chief

Journal of Commercial Biotechnology (2021) 26(4), 3–4. doi: 10.5912/jcb1003

WITH OUR Q4 2021 issue of J. Commercial Biotechnology, we continue our goal to continually improve impact on our audience. This is accomplished by attracting, developing and publishing insightful, timely, and relevant content that addresses the needs of our international, academic and industrial communities in the biopharma, MedTech, and Digital Health industries. Our approach is to balance curated, solicited content with high-quality contributed papers, all of which are peer reviewed by our editorial board, editorial advisory board, and other experts in our networks as needed.

We encourage our readers to check out our series of recent, curated Special Editions. We intend these to serve as ‘monographs’ to be used by readers and organizations in our target markets, both industrial and academic.

- “*The Business of Commercialization and Innovation*” (Vol.24, No. 1, 2018)
- “*Transforming Technology into High-Value Solutions for Compelling Biomedical Need: Entrepreneurship Bootcamp 2.0*” (Vol 24, No.4, 2019)
- “*Transformative Technologies*” (Vol. 25, No.4, 2020)
- “*Building and Leveraging Ecosystems and Clusters*” (Vol. 26, No. 1, 2021)
- “*Recognizing and Celebrating Innovation and Innovators in Our Industry*” (Vol. 26, No. 2, 2021).

These issues contain articles, case studies, From the Boardroom perspectives, and select book reviews. Vol. 26 also includes a *Hall of Fame* list of innovators and innovative companies in our industry.

“*What’s coming next?*” We are developing several special editions that are in planning for publication. These are focused on *Digital Healthcare*, *Precision Medicine*, & *Regenerative Medicine*. To the extent that we can, we intend to develop these products thru alliances and partnerships with leading academic institutions.

And, to include content from emerging, leading companies. For example, the *New Clinical and Commercial Opportunities in Digital Healthcare* edition is being kicked off with a virtual symposium at the University of California, San Diego on October 27, 2021 and followed up by curated papers to be published soon thereafter.

OVERVIEW OF THIS VOLUME

This volume, published as our Q4, 2021 edition is a “hybrid edition” that incorporates a topical/specially developed component, but it also incorporates unsolicited, contributed content from our community. So, we have divided the volume into two parts:

Part One continues our theme of Ecosystems and Clusters with a focus on innovation originating outside of the US and EU/UK. These emerging regions are challenged with bringing innovations into the local and broader worldwide markets. And, many of these regions also have unique healthcare challenges. Our focus in this volume is on globalization thru alliances, by growing critical mass ecosystems in southeast Asia, e. g. Australia, India, and some of the emerging regions there like Singapore. We also begin to address healthcare in the Middle East (UAE) and in Africa. Peter Pitts and his collaborators focus on healthcare in Dubai. Steve Sammut who has worked extensively in Africa over the years, has contributed an extensive paper that summarizes the challenges and opportunities in Africa. We believe his pioneering article should pave the way for development of the African healthcare ecosystem, and integration into the worldwide network. And, more importantly, to stimulate more industry-wide discussion and participation in developing “the African opportunity”, while addressing the huge healthcare need there.

Topical Articles related to globalization and alliances to accelerate innovation in biopharma contains largely solicited content around the theme of global collaboration and alliances. This theme extends our Ecosystems and Clusters issue, and is related to changes in the broader biopharma industry as driven by “evolution” to the Pharma 5.0 paradigm. In our introductory article, we discuss the challenges of commercialization faced by emerging regions in the world and propose some interesting alliance and partnership-based business models; c. f. Boni and Molloy, a “From the Boardroom”

Correspondence:

article. This is of course editorial opinion subject to further debate and development. We then move on to India, and southeast Asia as emerging regions. Also, more on alliances and partnerships (Jambulingham), and drug repurposing (Reaume), and a few mini case studies by John York and his associates on emerging international early stage companies.

TABLE OF CONTENTS FOR VOLUME NO. 26, NO. 3, 2021

TOPICAL ARTICLES RELATED TO GLOBALIZATION AND ALLIANCES TO ACCELERATE INNOVATION IN BIOPHARMA

- **Arthur A. Boni and Peter L. Molloy;** From the Boardroom, “A conversation on accelerating innovation in biopharma and life sciences through global collaboration and alliances”
- **Peter L. Molloy, Lester W. Johnson, and Michael Gilding,** “Australian Biotechnology: A 10-Year Study of Investor Performance”
- **Veena Somasundaram, Peter Soukas, Jenish Patel, and Steve Ferguson,** “Considerations for Potential Global Expansion of Serum Institute of India
- **Thani Jambulingham and Todd Saxton;** Strategic Alliance and Acquisition Performance: Impact of Interfirm Synergies and Motives in the Bio-Pharmaceutical Industry
- **Stephen M. Sammut,** “The Role of the Biotechnology Industry in Addressing Health Inequities in Africa: Strengthening the Entire Health Care Value Chain”
- **Andrew Reaume;** “Drug Repurposing as a Pharmaceutical Strategy: The Obvious Benefits are Real, but Beware of the Pitfalls That May be Less Apparent”